Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Commentary (Berger): Understanding and Treating Cancer-Related Fatigue

October 1, 2007
By Ann M. Berger, PhD, RN
Publication
Article
OncologyONCOLOGY Vol 21 No 11
Volume 21
Issue 11

Fatigue is the most common side effect of cancer and its treatment, and it frequently goes unrecognized and untreated. While the exact etiology of fatigue is unclear, numerous contributing factors that worsen fatigue can be clinically addressed. Substantial research supports physical exercise as an intervention for fatigue.

Management of cancer-related fatigue (fatigue) poses unique challenges to clinicians. The etiology of fatigue is poorly understood. Knowledge to date suggests that many factors can contribute to perceptions of fatigue. Attempts to correct identified related factors do not consistently relieve fatigue. In fact, pharmacological treatment for pain and depression may result in increased perceptions of fatigue. Translational research is needed to discover the etiology of fatigue in some of the most common cancer types and stages (ie, early breast cancer), to develop and test targeted and effective interventions, and to disseminate this knowledge.

Until knowledge regarding the etiology of fatigue is available, clinicians can use resources currently available. The National Comprehensive Cancer Network (NCCN) guidelines (www.nccn.org) recommend that fatigue be monitored on a routine basis in the clinical setting.[1] Despite the ease of using a 0-to-10 visual analog scale (VAS), routine assessment of fatigue is currently not a standard practice in oncology clinics. When opportunities to modify fatigue are missed, it can increase in severity and result in a need for more complex interventions. The adoption of routine assessment of fatigue, in addition to pain, must occur if fatigue is to be recognized and managed. The recommendation by Dr. Schwartz that patients with a 1-point increase in fatigue should be identified and receive some intervention is strongly supported by this reviewer.

Clinicians are encouraged to develop methods to record and track fatigue scores from each clinical visit. As suggested by Dr. Schwartz, the formal screening needs to include a review of symptoms (eg, pain, distress, sleep disturbances, anemia), an evaluation of disease status (eg, cancer, thyroid function), and a review of all current medications (prescription, over-the-counter, herbal). If sedating medications are being used, consideration of switching to less-sedating medications is highly recommended. If this is not possible, interventions to increase daytime alertness through pharmacologic and nonpharmacologic therapies may be appropriate. Clinicians are encouraged to use the ICD (International Classification of Diseases)-10 criteria to diagnose fatigue and a VAS for follow-up evaluation and treatment planning.[2]

The availability of Evidence-Based Practice (EBP) guidelines has provided clinicians with current information regarding recommended interventions. Dr. Schwartz provided information about the NCCN fatigue guidelines. It is important for clinicians to be aware of all NCCN supportive care guidelines, particularly those developed for pain and distress. The Oncology Nursing Society has developed EBP guidelines, referred to as ONS-PEP, that are available online and as pocket-sized cards that provide clinicians with interventions that are "Recommendations for Practice" for many symptoms, including fatigue (www.ons.org/outcomes).[3] Exercise has been recommended to relieve fatigue, and needs to be considered when planning treatment for most patients with this symptom.[4] The American Pain Society, the American Academy of Sleep Medicine, the American Society of Clinical Oncology, and Cochrane Reviews are additional recommended online resources to access current EBP guidelines.

Current knowledge needs to be moved to action in clinical oncology settings. Understanding of the methods by which to most effectively and efficiently translate knowledge into practice is a current and critical need in nursing.[5] Predicting research utilization among nurses has been evaluated, taking into account the influence at individual nurse, specialty, and hospital levels. The individual nurse level was found to be more influential than the specialty or hospital levels, and predicted by more time spent on the internet and lower levels of emotional exhaustion.[6] As Dr. Schwartz has suggested, nurses are in an ideal position to take a leadership role in assessing and managing fatigue. This reviewer challenges nurses to get involved in creating a clinical environment that promotes their emotional well-being and routine use of EBP guidelines in patients' fatigue-management plans.

References:

1. National Comprehensive Cancer Network: Practice guidelines. Cancer-related fatigue panel 2007 Guidelines, version 3.2007, August 2007. Rockledge, Pennsylvania. Available at: http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Accessed September 9, 2007.

2. Van Belle S, Paridaens R, Evers G, et al: Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: Proposal for use as a screening tool. Support Care Cancer 13(4): 246-254, 2005.

3. Oncology Nursing Society: Putting evidence into practice: Fatigue. Available at: http://www.ons.org/outcomes/volume1/fatigue.shtml. Accessed September 9, 2007.

4. Mitchell S, Beck S, Hood L, et al: Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 11(1):99-113, 2007.

5. Estabrooks C: Prologue: A program of research in knowledge translation. Nurs Res 56(4 suppl):S4-S6, 2007.

6. Estabrooks C, Midodzi W, Cummings G, et al: Predicting research use in nursing organizations: A multilevel analysis. Nurs Res 56(4 suppl):S7-S23, 2007.

Articles in this issue

Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
Study Supports Activity of Gemcitabine in Treatment of Early-Stage Breast Cancer
Remembering Martin D. Abeloff, MD
Merck to Donate 3 Million Doses of Cervical Cancer Vaccine to Third World Nations
New Lung Cancer Guidelines Oppose General CT Screening
Martin D. Abeloff, MD: Tributes and recollections
Cetuximab Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
FDA Approves Expanded Labeling for Alemtuzumab
FDA Fast Tracks PI-88 to Treat Postresection Liver Cancer
Common Early-Warning Symptoms of Ovarian Cancer Identified
Multiple Myeloma Trial Stopped Early Due to Significant Efficacy Advantage of Bortezomib
A Look Through the Prism of Cancer Nursing Today
Cancer Vaccines: A New Frontier in Prevention and Treatment
The Role of Surgery in the Management of Barrett's Esophagus
Advanced Breast Cancer: A Widening Spectrum of Options
Recent Videos
Related Content
Advertisement

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Related Content
Advertisement

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.